Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2014 11/21/2014 11/24/2014 11/25/2014 11/26/2014 Date
51.62(c) 50.94(c) 52.42(c) 51.51(c) 52.33 Last
1 190 184 1 531 035 1 225 943 1 346 405 329 445 Volume
+3.12% -1.32% +2.91% -1.74% +1.59% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer.The company operates in two segments: Drug Discovery & Development and... 
Sector
Biotechnology & Medical Research
Calendar
12/01 | 08:40amPresentation
Surperformance© rating of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More about the company
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 197 M
EBIT 2014 -60,0 M
Net income 2014 -73,0 M
Debt 2014 431 M
Yield 2014 -
Sales 2015 172 M
EBIT 2015 -110 M
Net income 2015 -139 M
Debt 2015 183 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 33,1x
EV / Sales 2015 36,4x
Capitalization 6 085 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
2h ago ISIS PHARMACEUTICALS : New Antisense Technology Findings Has Been Reported by Re..
1d ago ISIS PHARMACEUTICALS : Initiates Phase 3 Study of ISIS-SMN Rx in Children With S..
5d ago ISIS PHARMACEUTICALS : Entry into a Material Definitive Agreement, Creation of a..
5d ago ISIS PHARMACEUTICALS : -STAT3 Rx and -AR Rx Data Presented by AstraZeneca at Eur..
7d ago ISIS PHARMACEUTICALS : Prices Offering of $425 Million of 1.00% Convertible Seni..
7d ago ISIS PHARMACEUTICALS : Announces Proposed Offering of $425 Million of Convertibl..
7d ago ISIS PHARMACEUTICALS : AstraZeneca and Isis Pharmaceuticals to Co-Develop Target..
11/18 ISIS PHARMACEUTICALS : to Host Webcast to Discuss ISIS-FXI Rx Data Presented at ..
11/17 ISIS PHARMACEUTICALS : Cure SMA : Presents Isis Pharmaceuticals with SMA Breakth..
11/17 ISIS PHARMACEUTICALS : Assigned Patent
11/14 ASTRAZENECA : and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide De..
11/14 ISIS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
More news
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
08/14A resistance as obstacle
More Strategies


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF